Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd > its the TD trade show today
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(38)
•••
Comment by bligickaon Mar 29, 2021 8:55am
39 Views
Post# 32897142

RE:its the TD trade show today

RE:its the TD trade show todayLooks like TD wants out of this shiit show badly !!!
saintpeter wrote:
ecial terms and non-boardlot orders do not appear in Depth by Price  +Vertical+Columnar+Horizontal
V:VXL Depth by Order @07:51:01
Bid   Ask
Broker Size Price   Price Size Broker
80 National Bank 1,000 0.125   0.125 820 7 TD Sec
7 TD Sec 1,720 0.125   0.125 164,000 7 TD Sec
7 TD Sec 27,500 0.12   0.125 375,000 7 TD Sec
7 TD Sec 16,000 0.12   0.13 16,000 1 Anonymous
68 Leede 5,000 0.12   0.13 12,500 2 RBC
1 Anonymous 8,000 0.12   0.13 1,500 124 Questrade
79 CIBC 10,000 0.12   0.135 15,000 7 TD Sec
80 National Bank 500 0.12   0.135 2,500 80 National Bank
7 TD Sec 21,000 0.12   0.135 88,000 80 National Bank
80 National Bank 2,000 0.12   0.135 61,500 80 National Bank
Special terms orders and non-boardlot orders do not appear in Market Depth by Order



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities